Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Athanasios Anagnostopoulos

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
The Hematology Journal : the Official Journal of the European Haematology Association|March 30, 2004
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myelomaMeletios A Dimopoulos, George Hamilos, Athanasios Zomas, et al.
Leukemia & Lymphoma|September 17, 2004
Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progressionMeletios A Dimopoulos, Raymond Alexanian, Dimitra Gika, et al.
Leukemia & Lymphoma|October 30, 2004
Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factorsAthanasios Anagnostopoulos, Dimitra Gika, George Hamilos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factorsAristotle Bamias, Efstathios Kastritis, Christina Bamia, et al.
Seminars in Oncology|April 30, 2003
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaMorie A Gertz, Athanasios Anagnostopoulos, Kenneth Anderson, et al.
Haematologica|February 8, 2006
Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myelomaMeletios A Dimopoulos, Athanasios Anagnostopoulos, Evangelos Terpos, et al.
British Journal of Haematology|November 17, 2006
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myelomaEvangelos Terpos, Deborah J Heath, Amin Rahemtulla, et al.
Haematologica|November 21, 2007
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasoneEfstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou, et al.
Blood|July 27, 2007
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemiaPartow Kebriaei, Michelle A Detry, Sergio Giralt, et al.
Blood|April 20, 2004
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantationMarcos de Lima, Athanasios Anagnostopoulos, Mark Munsell, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
The Hematology Journal : the Official Journal of the European Haematology Association|March 30, 2004
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myelomaMeletios A Dimopoulos, George Hamilos, Athanasios Zomas, et al.
Leukemia & Lymphoma|September 17, 2004
Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progressionMeletios A Dimopoulos, Raymond Alexanian, Dimitra Gika, et al.
Leukemia & Lymphoma|October 30, 2004
Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factorsAthanasios Anagnostopoulos, Dimitra Gika, George Hamilos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factorsAristotle Bamias, Efstathios Kastritis, Christina Bamia, et al.
Seminars in Oncology|April 30, 2003
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaMorie A Gertz, Athanasios Anagnostopoulos, Kenneth Anderson, et al.
Haematologica|February 8, 2006
Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myelomaMeletios A Dimopoulos, Athanasios Anagnostopoulos, Evangelos Terpos, et al.
British Journal of Haematology|November 17, 2006
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myelomaEvangelos Terpos, Deborah J Heath, Amin Rahemtulla, et al.
Haematologica|November 21, 2007
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasoneEfstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou, et al.
Blood|July 27, 2007
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemiaPartow Kebriaei, Michelle A Detry, Sergio Giralt, et al.
Blood|April 20, 2004
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantationMarcos de Lima, Athanasios Anagnostopoulos, Mark Munsell, et al.
Pageof 6